Katja Stout, MBiochem (Oxon), MBA
Katja is a communications strategist and entrepreneur with over twenty years of international experience in the life sciences and pharmaceutical industry. A serial entrepreneur, she has founded two communications consultancies.
As Managing Director and Founder of Scius Communications, Katja supported Immunocore’s $320 million financing, Europe’s largest ever private round in life sciences. As Co-Founder and a Board Director of Northbank communications, a leading global specialist life sciences communications firms, Katja supported the company’s growth to over 35 staff and 100 clients prior to its successful sale to College Hill (now Instinctif).
Subsequently Katja spent four years at AstraZeneca firstly as Director of Partnering Communications in the business development team and supported AZ’s notable rise in the industry league tables from number 12 to number 3 as the ‘partner of choice’. She later became Vice President of Corporate Affairs, Global Product and Portfolio Strategy (GPPS) and was a member of the GPPS leadership team. In this role she was responsible for leading the communications for all of AstraZeneca’s global product brands and launching the new GPPS function internally.
Prior to founding Northbank, Katja held in-house roles at leading investment firms including SV Life Sciences, International BioTechnology Trust and Merlin Biosciences. She also worked at life sciences investor relations firm, Russell-Welsh (now GCI Healthcare), based in San Francisco, California. Earlier in her career, Katja was Head of communications and IR at Genset SA (now part of Merck Serono), a pioneer in personalised healthcare, listed on Nasdaq and the Nouveau Marche and based in Paris.
Katja has a Masters degree in Biochemistry from Oxford University and an MBA from Imperial College London.